Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/regulatory-science-in-neonates-lLg1ZaX0Lp
References (4)
-
V. Ramos-Martín, A. Johnson, J. Livermore, L. McEntee, J. Goodwin, S. Whalley, F. Docobo-Pérez, T. Felton, W. Zhao, É. Jacqz-Aigrain, M. Sharland, M. Turner, W. Hope (2016)
Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.The Journal of antimicrobial chemotherapy, 71 4
-
M. Turner, J. Davis, S. McCune, Ralph Bax, R. Portman, Lynn Hudson (2016)
The International Neonatal Consortium: collaborating to advance regulatory science for neonatesPediatric Research, 80
-
(2017)
Reforming clinical trials in drug development: impact of targeted therapies. http: //www.fda.gov/downloads/AboutFDA /CentersOffices /OfficeofMedicalProductsandTobacco/CDER /UCM530409.pdf -
(2017)
and Drug Administration
- Publisher
- American Medical Association
- Copyright
- Copyright 2017 American Medical Association. All Rights Reserved.
- ISSN
- 2168-6203
- eISSN
- 2168-6211
- DOI
- 10.1001/jamapediatrics.2017.1360
- Publisher site
- See Article on Publisher Site
Abstract
This Viewpoint highlights the importance of collecting high-quality data, rationally using data, and having a framework for evaluating drugs in regulatory science.
Journal
JAMA Pediatrics – American Medical Association
Published: Aug 12, 2017